These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26081027)

  • 41. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon-induced pulmonary hypertension: an update.
    Savale L; Chaumais MC; O'Connell C; Humbert M; Sitbon O
    Curr Opin Pulm Med; 2016 Sep; 22(5):415-20. PubMed ID: 27387101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
    Zhang WH; Liu CP; Zhang YJ; Ji YQ; Lu WX; Zeng Q
    Scand Cardiovasc J; 2012 Dec; 46(6):374-80. PubMed ID: 22971207
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
    Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
    J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
    Park MH
    Catheter Cardiovasc Interv; 2008 Feb; 71(2):205-13. PubMed ID: 18327839
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment.
    Zhang YJ; Li MH; Chen SL
    EuroIntervention; 2013 May; 9 Suppl R():R149-54. PubMed ID: 23732148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New horizons in pulmonary arterial hypertension therapies.
    Galiè N; Ghofrani AH
    Eur Respir Rev; 2013 Dec; 22(130):503-14. PubMed ID: 24293466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral treprostinil for the treatment of pulmonary arterial hypertension.
    de Lartigue J
    Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Combination therapy in the management of pulmonary arterial hypertension.
    Buckley MS; Staib RL; Wicks LM
    Int J Clin Pract Suppl; 2013 May; (179):13-23. PubMed ID: 23578069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study.
    Bendayan D; Shitrit D; Kramer MR
    Respirology; 2008 Nov; 13(6):916-8. PubMed ID: 18811891
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current status of pulmonary arterial hypertension in Korea.
    Jang AY; Chung WJ
    Korean J Intern Med; 2019 Jul; 34(4):696-707. PubMed ID: 31272141
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pulmonary arterial hypertension in patients treated with interferon.
    Savale L; Sattler C; Günther S; Montani D; Chaumais MC; Perrin S; Jaïs X; Seferian A; Jovan R; Bulifon S; Parent F; Simonneau G; Humbert M; Sitbon O
    Eur Respir J; 2014 Dec; 44(6):1627-34. PubMed ID: 25323231
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emerging treatments for pulmonary arterial hypertension.
    Rosenzweig EB
    Expert Opin Emerg Drugs; 2006 Nov; 11(4):609-19. PubMed ID: 17064221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment Discontinuation or Interruption in Pulmonary Arterial Hypertension.
    Narechania S; Torbic H; Tonelli AR
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):131-141. PubMed ID: 31594400
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
    Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Living-donor lobar lung transplantation for pulmonary arterial hypertension after failure of epoprostenol therapy.
    Date H; Kusano KF; Matsubara H; Ogawa A; Fujio H; Miyaji K; Okazaki M; Yamane M; Toyooka S; Aoe M; Sano Y; Hanazaki M; Goto K; Kasahara S; Sano S; Ohe T
    J Am Coll Cardiol; 2007 Aug; 50(6):523-7. PubMed ID: 17678735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of Chronic Thromboembolic Pulmonary Hypertension: The Role of Medical Therapy and Balloon Pulmonary Angioplasty.
    Fernandes TM; Poch DS; Auger WR
    Methodist Debakey Cardiovasc J; 2016; 12(4):205-212. PubMed ID: 28289495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.